X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Health & Nutrition

Sports Nutrition Leader Iovate Health Sciences Announces Strategic Investment by Xiwang Foodstuffs to Accelerate Growth in China

Content Team by Content Team
1st October 2017
in Health & Nutrition

Iovate Health Sciences International, Inc. announced that it has reached a definitive agreement to receive a majority equity investment from Shenzhen-listed Xiwang Foodstuffs Co., Ltd. (“Xiwang Food”). The transaction will accelerate Iovate’s growth in China and provide its brands with significant product expansion globally.

The Iovate Executive Team states, “Over the last 20 years, our teams at Iovate have built a business that has given our brands an industry-leading position in North America and throughout the world. Through this strategic partnership with well-established consumer products leader Xiwang, we now have the unique opportunity to accelerate our international growth, particularly in the China market. MuscleTech is already gaining significant momentum in China, and this partnership solidifies that position into what we believe will deliver significant growth in a reasonably short period of time.”

Iovate will maintain its North American headquarters in Oakville, Canada. All Executives and Senior Leaders, as well as its 330 existing employees, will remain in place to take the business to the next level of growth. At the close of this transaction, Iovate’s CEO will maintain a significant ownership stake in Iovate and will remain on as CEO.

The proposed transaction is subject to the satisfaction of closing conditions, including customary regulatory approvals in Canada and China. The transaction is expected to close later in the calendar year.

Houlihan Lokey is serving as exclusive financial advisor to Iovate and assisting in structuring and negotiating the transaction. Goodmans LLP is serving as the legal advisor to Iovate.

Founded in 1995 and based in Oakville, Canada, Iovate is a dynamic, leading-edge nutritional company that delivers some of the highest quality, most innovative and effective active nutrition products in the world. With brand innovations like MuscleTech, Six Star Pro Nutrition, Purely Inspired and Hydroxycut, the company is committed to being the number one active nutrition and weight management supplement company in the world. Iovate distributes across all major channels of distribution, including food, drug, mass and club, health food stores and online, as well as in more than 130 countries worldwide. Iovate products are available nationwide at GNC, The Vitamin Shoppe, Bodybuilding.com, WalMart, Target, Walgreen’s, Sam’s Club, Amazon.com and other fine retailers.

Founded in 2007 and based in Shandong Province, China, Xiwang Food is the leading Chinese player in healthy consumable oils such as corn oil and flaxseed oil. Xiwang Food has a vast sales and distribution network, selling its products in more than 85,000 mass merchandise stores and over 2,000 drug stores in China. Xiwang Food is listed on the Shenzhen Stock Exchange (SZ000639) since 2011 and currently has more than 5,000 employees. Xiwang Food is a subsidiary of Xiwang Group Company Limited (“Xiwang Group”), a large industrial enterprise company that also maintains investments in specialty steel, real estate, energy and beverages, among other sectors. Xiwang Group is ranked among the 500 largest companies in China with consolidated revenue in excess of $5 billion.

Previous Post

Recipharm equips Lisbon facility for US and European serialisation

Next Post

Bharat Biotech’s new typhoid vaccine shows high efficacy in study

Related Posts

Bio-Gate and Avicanna complete first phase of development on CBD and Micro Silver BG based skin care products for global commercialization
Health & Nutrition

Bio-Gate and Avicanna complete first phase of development on CBD and Micro Silver BG based skin care products for global commercialization

30th June 2021
Good nutrition can contribute to keeping COVID-19 and other diseases away
Health & Nutrition

Good nutrition can contribute to keeping COVID-19 and other diseases away

12th October 2020
Danone Ltd invests €100m in specialized nutrition in China
Health & Nutrition

Danone Ltd invests €100m in specialized nutrition in China

20th July 2020
DuPont Nutrition & Biosciences Enters into Collaboration with Microbiome Specialist MRM Health
Health & Nutrition

DuPont Nutrition & Biosciences Enters into Collaboration with Microbiome Specialist MRM Health

25th February 2020
Herbalife Nutrition Launches Beta Heart for Better Cardiovascular Health
Health & Nutrition

Herbalife Nutrition Launches Beta Heart for Better Cardiovascular Health

24th January 2020
Royal DSM Completes Acquisition of Specialty Dairy Solutions Provider CSK
Health & Nutrition

Royal DSM Completes Acquisition of Specialty Dairy Solutions Provider CSK

7th January 2020
Next Post

Bharat Biotech’s new typhoid vaccine shows high efficacy in study

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In